Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Children 6-35 Months
NCT04363359Phase 2Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of quadrivalent influenza vaccine in influenza, sponsored by Shanghai Institute of Biological Products. Started Jan 2020; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04363359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363359.